Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids

Panu K. Luukkonen¹,²*, Auli Nick¹,³, Auli Nick¹,³, Maarit Hölttä-Vuori¹,³, Christoph Thiele⁴, Elina Isokuortti¹,², Susanna Lallukka-Brück¹,², You Zhou¹,⁵,⁶, Antti Hakkarainen⁷,⁸, Nina Lundbom⁷, Markku Peltonen⁹, Marju Orho-Melander¹⁰, Matej Orešič¹¹,¹², Tuulia Hyötyläinen¹³, Leanne Hodson¹⁴, Elina Ikonen¹,³,**,§, Hannele Yki-Järvinen¹,²,***,§

¹Minerva Foundation Institute for Medical Research, Helsinki, Finland, ²Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Faculty of Medicine, Department of Anatomy, University of Helsinki, Helsinki, Finland, ⁴LIMES Institute, Bonn University, Bonn, Germany, ⁵Systems Immunity Research Institute, Cardiff University, Cardiff, UK, ⁶Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK, ⁷Department of Radiology, HUS Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ⁸Department of Neuroscience and Biomedical Engineering, Aalto University School of Science, Espoo, Finland, ⁹Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland, ¹⁰Department of Clinical Sciences, Lund University, Malmö, Sweden, ¹¹Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland, ¹²School of Medical Sciences, Örebro University, Örebro, Sweden, ¹³Department of Chemistry, Örebro University, Örebro, Sweden, ¹⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK, *Authors share co-first authorship, **Authors share co-last authorship, § Corresponding Author.
CORRESPONDING AUTHORS:
Hannele Yki-Järvinen, MD, FRCP
Biomedicum 1, Room C426b
Haartmaninkatu 8
00290 Helsinki, Finland
+358 50 562 6899
hannele.yki-jarvinen@helsinki.fi

Elina Ikonen, MD
Biomedicum 1, Room B112b
Haartmaninkatu 8
00290 Helsinki, Finland
+358 50 4485050
elina.ikonen@helsinki.fi

DECLARATION OF INTERESTS
The authors have declared that no conflict of interest exists.
Human PNPLA3 I148M variant

Liver in vivo

Polyunsaturated fatty acid
Saturated fatty acid

VLDL-TG

Lipolysis in cells

TG ➔ DAG ➔ PC

Excluded by PNPLA3 I148M variant
ABSTRACT

The common patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant I148M predisposes to non-alcoholic liver disease but not its metabolic sequelae. We compared the handling of labeled polyunsaturated and saturated fatty acids (PUFA and SFA) in vivo in humans and in cells harboring different PNPLA3 genotypes. In 148M homozygous individuals, triglycerides (TGs) in very low-density lipoproteins (VLDL) were depleted of PUFA both under fasting and postprandial conditions compared to 148I homozygotes, and the PUFA/SFA ratio in VLDL-TGs was lower relative to the chylomicron precursor pool. In human PNPLA3-148M and PNPLA3-knockout cells, PUFA but not SFA incorporation into TGs was increased at the expense of phosphatidylcholines, and under lipolytic conditions PUFA containing diacylglycerols (DAGs) accumulated compared to PNPLA3-148I cells. Polyunsaturated TGs were increased while PCs were decreased in the human liver in 148M homozygous individuals as compared to 148I homozygotes. We conclude that human PNPLA3-I148M is a loss of function allele that remodels liver TGs in a polyunsaturated direction by impairing hydrolysis/transacylation of PUFA from DAGs to feed phosphatidylcholine synthesis.

KEYWORDS: Non-alcoholic fatty liver disease, triglycerides, lipids, lipase
INTRODUCTION

The I148M variant in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is found worldwide in 30-50% of all subjects (1). It increases intrahepatocellular triglycerides (IHTGs) and risks of non-alcoholic steatohepatitis (NASH), alcoholic and non-alcoholic cirrhosis and hepatocellular carcinoma (2). Unlike in non-alcoholic fatty liver disease (NAFLD) associated with obesity and metabolic syndrome, carriers with NAFLD due to the I148M gene variant are neither insulin resistant nor predisposed to develop metabolic sequelae such as cardiovascular disease compared to non-carriers (1). Indeed, several studies have recently shown the gene variant to be protective against cardiovascular disease (3, 4).

In humans, hepatic TGs are markedly enriched in polyunsaturated fatty acids (PUFA) in carriers of the PNPLA3 I148M variant compared to non-carriers (5). This lipidome differs from the NAFLD lipidome associated with insulin resistance, in which liver is enriched in predominantly saturated or monounsaturated TGs (5). The human lipidomic data of NAFLD in PNPLA3 variant carriers closely resemble the hepatic lipidomic profile of PNPLA3 knock-out (ko) mice (6, 7). In the latter study, PNPLA3 was proposed to act as a transacylase transferring PUFAs from TG to lyso-phospholipids or as a TG hydrolase hydrolyzing PUFAs from TGs in a remodeling pathway for lipid droplet phospholipids (7).

However, data from mouse models are not easy to reconcile with the human data. PNPLA3-ko mice accumulate polyunsaturated TGs but do not develop hepatic steatosis (6-8). Opposite to humans and knock-in mice expressing a catalytically inactive
PNPLA3 (PNPLA3-S47A-ki), PUFAs are depleted in hepatic TGs in I148M knock-in mice, i.e. in mice in which the I148M has been introduced to the endogenous mouse PNPLA3 gene (7). Mouse PNPLA3 is approximately 68% homologous with human PNPLA3 (9). This difference could contribute to the discrepant results in mice as compared to humans. Regarding cell models, hepatic cell lines such as HuH7 and HepG2 are not ideal for studying the function of the PNPLA3 I148M variant as both cell lines are homozygous for the variant allele (10, 11). There are no studies addressing the function of the PNPLA3 I148M variant in humans in vivo or in vitro in human cells that do not endogenously express the I148M variant and in which the variant has been knocked-in rather than overexpressed.

In the present study, we wished to determine why PUFAs are enriched in TGs in the human liver. This is important for understanding the pathogenesis of the most important genetic risk factor of NAFLD. To this end, we compared the hepatic handling of labeled PUFAs (13C-18:2) and saturated fatty acids (SFAs, 13C-16:0) and the composition of VLDL in homozygous carriers and non-carriers of the PNPLA3 I148M variant. Furthermore, by using CRISPR-Cas9 we engineered human cells homozygous for the PNPLA3 148I allele (PNPLA3-148I, wt) to generate cell lines with a homozygous I148M substitution (PNPLA3-148M-ki) or a homozygous PNPLA3 deletion (PNPLA3-ko). In these cells we employed “click” chemistry of alkyne-labeled C-18:2 and C-16:0 FAs to analyze rapid fatty acid fluxes during lipogenesis and lipolysis. Finally, we compared the lipid composition of human liver biopsies between homozygous carriers and non-carriers of the I148M variant.
RESULTS

Increased IHTGs in homozygous 148M variant allele carriers (PNPLA3\textsuperscript{148MM}) compared to non-carriers (PNPLA3\textsuperscript{148II})

Characteristics of the PNPLA3\textsuperscript{148II} and PNPLA3\textsuperscript{148MM} groups are shown in Table 1. The PNPLA3\textsuperscript{148MM} group had a significantly and 3.5-fold higher IHTG content than the PNPLA3\textsuperscript{148II} group (6.3 [4.5 – 14.6] vs. 1.8 [1.0 – 6.7] %) (Table 1). The PNPLA3\textsuperscript{148II} and PNPLA3\textsuperscript{148MM} groups were similar with respect to age, gender, glucose and insulin concentrations and BMI (Table 1). There were no significant differences between the groups in physical activity or dietary intake as determined by 1-week accelerometer data and analysis of 3-day dietary records (Table S1).

Deficiency of polyunsaturated TGs in VLDL in the PNPLA3\textsuperscript{148MM} as compared to the PNPLA3\textsuperscript{148II} group

Total concentrations of plasma TG, free fatty acids (FFA), VLDL-TG and chylomicron-TG and glucose and serum insulin concentrations were similar between the PNPLA3\textsuperscript{148MM} and PNPLA3\textsuperscript{148II} groups in the fasting state and postprandially at every time point (Figure 1). Lipidomic analysis of VLDL was performed for detailed characterization of VLDL-TGs in the fasting state and postprandially. The relationship between the number of double bonds in VLDL-TGs and the ratio of the mean absolute concentrations of corresponding VLDL-TGs in the PNPLA3\textsuperscript{148MM} as compared to the PNPLA3\textsuperscript{148II} group are shown in Figure 2. The number of double bonds was inversely related to the ratios of VLDL-TGs in PNPLA3\textsuperscript{148MM} vs. PNPLA3\textsuperscript{148II} in the fasting state and at 120 min, 300 min and 420 min postprandially (Figure 2). Thus, although total concentrations of VLDL-TGs were similar (Figure 1), the TGs secreted from the liver
in VLDL before and during the meal were deficient in polyunsaturated TGs in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group.

**Deficiency of PUFA in VLDL-TG fatty acids in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group**

The percentage of distinct fatty acids of total fatty acids in VLDL-TGs in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group in the fasting state are shown in Figure 3A. Saturated palmitate (16:0), monounsaturated oleate (18:1) and polyunsaturated linoleate (18:2) were the most abundant FAs in VLDL-TGs in both groups (Figure 3A). The percentage of 18:2 fatty acid in VLDL-TG fatty acids was significantly lower in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group in the fasting state (Figure 3A) and during the entire postprandial period (Figure 3B-C). In contrast, the percentage of SFA 16:0 in VLDL-TG fatty acids was significantly higher in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group in the fasting state (Figure 3A) and during the postprandial period (Figure 3B, D).

The relationship between the number of double bonds in VLDL-TG fatty acids and the ratio of the mean absolute concentrations of corresponding VLDL-TG fatty acids in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group are shown in Figure 3E. The number of double bonds was inversely related to the ratios of VLDL-TG fatty acids in homozygous carriers vs. non-carriers during the postprandial period (Figure 3E). These data show that there is polyunsaturated fatty acid deficiency in VLDL-TG in 148M carriers and support the hypothesis that PUFAs are retained in the liver in PNPLA3^{148MM} as compared to the PNPLA3^{148II} group.
In vivo evidence of retention of labeled $^{13}$C-18:2 PUFA in the human liver in PNPLA3$^{148\text{MM}}$ compared to PNPLA3$^{148\text{II}}$ group

Dietary fatty acids are transported from the intestinal lumen to the circulation in chylomicron-TGs, which then undergo hydrolysis and are taken up by the liver (12). VLDL-TGs are produced exclusively by the liver (12). Thus, to compare handling of PUFAs and SFAs in the liver, we calculated their ratio in VLDL-TGs and chylomicron-TGs. The PNPLA3$^{148\text{MM}}$ group had a significantly lower $^{13}$C-18:2/$^{13}$C-16:0 ratio in VLDL-TGs compared to the PNPLA3$^{148\text{II}}$ group (p<0.01) when related to the corresponding ratio in the chylomicron precursor pool (Figure 3F). There were no differences in enrichment of either of the fatty acids in the chylomicron precursor pools between the PNPLA3$^{148\text{MM}}$ and the PNPLA3$^{148\text{II}}$ (data not shown).

Increased storage of neutral lipids in homozygous PNPLA3 148M-ki human cells

We used human epidermoid carcinoma A431 cells that are readily amenable for genetic manipulation and homozygous for the PNPLA3-148I allele. PNPLA3 is expressed in the skin (13) and in A431 cells at levels roughly comparable to HepG2 cells (Human Protein Atlas). We have used these cells in our earlier studies on lipid processing and storage (14, 15). Starting from the wt PNPLA3 cells, we engineered PNPLA3-ko cells as well as cells expressing the 148M allele as homozygous (PNPLA3-148M-ki) and generated stable cell lines. Under basal culture conditions, the PNPLA3-148M-ki cells exhibited, as expected, elevated neutral lipid levels (TGs and cholesteryl esters, CEs) compared to wt cells (30.67±4.7 [SEM] ng lipid/ µg protein versus 18.27±2.4 [SEM], N=6). We also engineered cells stably expressing GFP-tagged PNPLA3-148I or PNPLA3-148M on a PNPLA3-ko background. In these cells, both forms of PNPLA3
are expressed at similar levels (Figure S2A) and associate with lipid droplets (Figure S2B). These results are in keeping with our previous findings in hepatoma cells (16).

Increased storage of PUFAs but not SFAs in PNPLA3 148M-ki and PNPLA3-ko cells

We then studied how addition of saturated or increasingly unsaturated exogenous fatty acids affects lipid storage in A431 cells. Fluorescence microscopy revealed that all three cell lines generated lipid droplets when exposed to fatty acids for 24 h. Expectedly, oleic and palmitic acid were potent inducers of lipid droplets, and PUFAs were less efficient (Figure 4). However, lipid droplet accumulation induced by PUFAs was strikingly increased in PNPLA3-148M-ki and PNPLA3-ko cells. This effect was not observed with saturated or monounsaturated FA. These results show that lack of PNPLA3 activity results in preferential sequestering of PUFAs to neutral lipids.

Increased incorporation of PUFAs to TGs and decreased incorporation to PCs in PNPLA3-148M-ki and PNPLA3-ko cells

Click chemistry is powerful for tracing rapid fatty acid metabolism (15, 17). Using this approach, we compared how alkyne-palmitate and alkyne-linoleate are metabolized into major cellular lipid species during 15 min of labeling. The partitioning of alkyne-palmitate to phosphatidylcholines (PCs), diacylglycerols (DAGs) and TGs was similar between PNPLA3 genotypes (Figure 5A). At this time point the majority of alkyne-linoleate was found in PCs in all cell lines (Figure 5B). However, in PNPLA3-148M-ki and PNPLA3-ko cells, the fraction of alkyne-linoleate in PC was significantly reduced and in TGs concomitantly increased as compared to wt (Figure 5B). Moreover, the percentage of FFA was higher in PNPLA3-148M-ki and PNPLA3-ko cells
(29.6%±2.4 and 29.1%±2.5 respectively, N=9) compared to wt cells (21.3%±3.7, N=9), implying defects in incorporation of PUFAs into PC.

**Accumulation of DAGs in PNPLA3-148M-ki and PNPLA3-ko cells in lipolytic conditions**

Due to the observed differences between PNPLA3 genotypes in PUFA metabolism and the reported PNPLA3 lipase activity (18, 19), we next measured release of linoleic acid from TG stores. To this end, we incubated wt A431 cells with alkyne-linoleate for 1 h in the presence of a cholesterol esterification inhibitor (PKF-035; to ensure maximal neutral lipid deposition as TGs). The cells were then either immediately harvested (0 min chase) or incubated for 15, 30 or 60 min (chase) in the presence of diacylglycerol O-acyltransferase (DGAT) 1 and 2 inhibitors that prevent TG synthesis as well as a cholesterol esterification inhibitor. As the inhibitors prevent fatty acid re-esterification to neutral lipids, under these conditions, cells start to hydrolyze the generated TGs. As expected, alkyne-linoleate containing TGs and DAGs decreased during chase and this was paralleled by increased partitioning of alkyne-linoleate into phospholipids, with marginal levels of FFAs (**Figure S3A**).

When the effect of PNPLA3 genotype on TG hydrolysis was investigated, we found that both PNPLA3-148M-ki and PNPLA3-ko cells had elevated TG levels at the end of alkyne-linoleate labeling as compared to PNPLA3-148I (**Figure 5C**). The increase in TGs in PNPLA3-ko and 148M-ki cells is consistent with the idea that the human gene variant increases TGs because it acts as a loss-of function variant. During the 1 h chase, TGs started to diminish but stayed elevated in both genotypes relative to PNPLA3-148I cells (**Figure 5C**). Of note, although TGs stayed elevated in PNPLA3-ko and 148M-ki
cells compared to wt PNPLA3-148I cells, we did not observe major differences in the hydrolysis rate of TGs under lipolytic conditions between these cells. This does not favor the idea that PNPLA3 functions mainly in TG hydrolysis.

Strikingly, under lipolytic conditions we observed a pronounced increase in DAGs in both PNPLA3-148M-ki and PNPLA3-ko cells as compared to wt (Figure 5C). This effect was not observed during the 15 min labeling (Figure 5B), suggesting that the increase was not due to increased generation of DAGs but rather to their impaired hydrolysis. In PNPLA3-148M-ki and PNPLA3-ko cells, there was also a tendency for decreased incorporation of alkyne-linoleate into PCs, but the difference was not significant (Figure S3B). This is not surprising, because during the course of hour(s) linoleic acid can end up in the PC pool via several pathways.

**Polyunsaturated TGs are enriched while PCs are deficient in the human liver in homozygous carriers of the PNPLA3 I148M variant compared to non-carriers**

Since polyunsaturated TGs accumulated in the PNPLA3-148 cells at the expense of PCs, we next asked whether the enrichment of polyunsaturated TGs would be associated with a decrease in PCs in the human liver in homozygous carriers of the PNPLA3 I148M variant as compared to non-carriers. To this end, we re-analyzed previously described data of human liver lipidome (5) in homozygous I148M variant carriers and non-carriers. As previously reported, the livers of the I148M variant carriers were enriched in polyunsaturated TGs, such as TG(56:6) and TG(58:6) (p<0.05) (Figure 6). Consistent with the in vitro data, the livers of homozygous I148M variant carriers were deficient in multiple PCs such as PC(36:6) and PC(32:2) as compared to non-carriers (p<0.05) (Figure 6).
DISCUSSION

Liver TGs in human liver biopsies are markedly polyunsaturated in PNPLA3\textsuperscript{148M} gene variant carriers as compared to non-carriers (5). The present data show, using a combination of GC, UHPLC-MS and stable isotope techniques that this reflects increased retention of PUFAs in the liver and results in PUFA deficiency in VLDL-TG secreted by the liver. The evidence from the \textit{in vivo} studies can be summarized as follows. In the PNPLA3\textsuperscript{148MM} as compared to the PNPLA3\textsuperscript{148II} group both in the fasting state and postprandially: i) the number of double bonds in VLDL-TGs measured by UHPLC-MS (Figure 2) and ii) the proportion of polyunsaturated linoleate (18:2) fatty acid (GC) in VLDL-TGs (Figure 3C) were lower and iii) PUFAs in VLDL-TGs (GC) were deficient (Figure 3E). When the subjects ingested equal amounts of a saturated (16:0) and a polyunsaturated (18:2) fatty acid in a meal labeled with respective stable isotope tracers, the ratio of labeled 18:2 vs. 16:0 was lower in the PNPLA3\textsuperscript{148MM} than the PNPLA3\textsuperscript{148II} group (Figure 3F). There are no previous studies comparing composition of VLDL-TG either in the fasting state or postprandially between PNPLA3\textsuperscript{148MM} and PNPLA3\textsuperscript{148II} groups or kinetic studies addressing function of the 148M variant in humans.

To explore the mechanism explaining retention of PUFAs in the human liver, we engineered PNPLA3-ko cells as well as cells expressing the 148M allele as homozygous (PNPLA3-148M-ki) and generated stable cell lines. This knock-in model of the PNPLA3 variant is the first to examine the impact of endogenous levels of the human PNPLA3 variant on lipid composition and metabolism. In previous studies using human cell lines (16, 20, 21) the gene variant was overexpressed, potentially causing artefacts.
Lipid droplet accumulation induced by PUFAs but not by saturated or monounsaturated FA was strikingly increased in PNPLA3-148M-ki and PNPLA3-ko cells. These results suggest that lack of PNPLA3 activity results in preferential sequestering of PUFAs to neutral lipids and that the 148M variant resembles loss of PNPLA3 function in human cells.

Studies using click chemistry allow tracing of rapid changes in fatty acid metabolism (17). In PNPLA3-148M-ki and PNPLA3-ko cells, the fraction of alkyne-linoleate in PC was significantly reduced and in TGs increased as compared to wt cells. In human liver samples, concentrations of polyunsaturated PCs were significantly decreased while TGs were increased in the livers of homozygous carriers of the PNPLA3 I148M variant as compared to non-carriers (Figure 6). These data closely resemble those of knock-in mice expressing a catalytically inactive PNPLA3 variant (PNPLA3-S47A-ki mice) but oppose those characterizing PNPLA3-148M-ki mice (7). In these mice, very long chain PUFAs are enriched in TGs and depleted in phospholipids. Therefore, the human PNPLA3-148M variant resembles human and mouse PNPLA3 loss of function.

In PNPLA3-148M and PNPLA3-ko cells, PUFA containing DAGs accumulated under lipolytic conditions compared to PNPLA3-148I cells. This was paralleled by a tendency for decreased incorporation of PUFA into PCs in PNPLA3-148M and PNPLA3-ko cells. These data suggest that PNPLA3 promotes transfer of PUFAs from DAGs to generate polyunsaturated PCs, thus refining the model proposed by Mitsche et al. (7). It is conceivable that PNPLA3 acts as a PUFA-specific transacylase, catalyzing the transfer of PUFAs in DAGs generated from TG hydrolysis (such as 2,3-DAGs), to yield
DAGs compatible with PC generation (1,2-DAGs). Alternatively, PNPLA3 may act as a PUFA-specific lipase hydrolyzing PUFAs from DAGs, to be used for the synthesis of PUFA-containing PCs. Importantly, the PNPLA3-148M-variant had similar effects to lipid metabolism as PNPLA3 deletion. While we cannot exclude the possibility that I148M substitution results in altered substrate specificity of the enzyme, the data strongly suggest that the I148M substitution results in loss of PNPLA3 activity in human cells. Either way, I148M remodels liver TGs in the human liver in a polyunsaturated direction (22). This lipid composition opposes the saturated TG composition characterizing liver in NAFLD associated with insulin resistance (‘Metabolic NAFLD’) (5, 23). The retention of polyunsaturated TGs in the liver may explain why carriers of the PNPLA3 gene variant are protected against cardiovascular disease despite having an increase in liver fat content (3, 4).
METHODS

Subjects
A total of 26 subjects who were homozygous for either the C or the G allele at rs738409 and fulfilled the inclusion and exclusion criteria (vide infra) were recruited among non-diabetic individuals who had previously been genotyped for PNPLA3 at rs738409 in our laboratory (24) or in the population-based National FINRISK 2007 (25).

Inclusion criteria included: (a) age 18 to 65 years; (b) PNPLA3 genotype CC or GG at rs738409; (c) alcohol consumption less than 20 g per day for women and less than 30 g per day for men. Exclusion criteria included: (a) known acute or chronic disease other than obesity, NAFLD or hypertension on the basis of medical history, physical examination and standard laboratory tests (complete blood count, serum creatinine, electrolyte concentrations); (b) clinical or biochemical evidence of liver disease other than NAFLD, or clinical signs or symptoms of inborn errors of metabolism; (c) history or current use of toxins or drugs associated with liver steatosis, (d) history or current use of lipid lowering medications; (e) pregnancy or lactation.

Clinical study design
The study consisted of i) a screening visit, ii) a metabolic study visit and iii) a visit to the imaging center for quantification of IHTG using proton magnetic resonance spectroscopy (1H-MRS).

The screening visit was performed after an overnight fast. A history and physical examination were performed to review the inclusion and exclusion criteria. Blood
samples were obtained for measurement of circulating blood count, glucose, HbA1c, serum insulin, thyroid stimulating hormone, hepatitis C virus antibody, plasma glucose, low density lipoprotein (LDL)- and high density lipoprotein (HDL)-cholesterol, triglyceride, albumin, thromboplastin time, C-reactive protein, sodium, potassium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT) concentrations as described (24).

After the screening visit, the subjects wore portable accelerometers (GT3X, Actigraph, Pensacola, FL) for 7 days to estimate their physical activity. The subjects were asked to collect a 3-day dietary record to determine their baseline dietary composition. The dietary records were analyzed using the AivoDiet software (version 2.0.2.3; Aivo Finland, Turku, Finland).

*Metabolic study visit.* For 3 days prior to the *metabolic study* day, the subjects were asked to avoid foods naturally enriched in 13C (such as sea food, corn, and sugar), alcohol, and strenuous exercise. In the previous evening before the metabolic study, the subjects consumed a standardized meal (a vegetarian sandwich, 330 kcal, 21 g fat, 25 g carbohydrate and 9 g protein, produced by Ravioli, Helsinki, Finland). The subjects came to the clinical research center after an overnight fast. Body composition (InBody 720; BioSpace, Seoul, Korea), weight, height and waist circumference were measured as described (5). A cannula was inserted into an antecubital vein, and baseline blood samples were taken to measure plasma albumin, AST, ALT, ALP, GGT, bilirubin, C-peptide, glucose, LDL and HDL cholesterol and triglyceride concentrations as well as serum insulin concentrations. Participants were then fed a mixed test meal containing
44 g carbohydrate, 10 g protein and 37 g fat, with 100 mg of [U\textsuperscript{13}C]palmitic acid and
100 mg of [U\textsuperscript{13}C]linoleic acid (both from Cambridge Isotopes, UK) added to trace the
fate of the dietary fatty acids (26). The meal consisted of 40 g Kellogg’s Rice Krispies
with 200 g skimmed milk, and a chocolate milkshake containing 20 g butter, 20 g
rapeseed oil, sweetener and cocoa powder.

Blood samples were taken at 0, 60, 120, 180, 240, 300, 360, and 420 min after the
consumption of the test meal for measurement of plasma glucose, TG, free fatty acids
(FFA), and serum insulin concentrations, and at 0, 120, 180, 240, 300, 360 and 420 min
for isolation of very-low density lipoprotein (VLDL) and chylomicrons by
ultracentrifugation as described (27). The fatty acid composition and concentrations of
\textsuperscript{13}C-18:2 and \textsuperscript{13}C-16:0 FAs were determined in total plasma, plasma FFA and the VLDL
and chylomicron fractions (vide infra). Lipidomics analyses (vide infra) were
performed of the VLDL fraction using UHPLC-MS at the time points of 0, 120 and 420
min.

\textit{Imaging visit}. Before the metabolic study visit, the subjects underwent \textsuperscript{1}H-MRS to
quantify IHTG content (vide infra).

\textbf{Isolation of VLDL and chylomicron fractions}

Separations of chylomicron of Svedberg flotation rate (S\textsubscript{f}) >400 and VLDL-rich
fraction (S\textsubscript{f}20-400) were made by sequential flotation using density gradient
ultracentrifugation (Beckman L-80, Beckman Coulter, Brea, CA) as previously
described (23).
FA isotopic enrichment
To determine the specific FA composition and isotopic enrichment, total lipids were extracted from plasma, and VLDL and chylomicrons and FA methyl esters (FAMEs) prepared (28, 29). The FA compositions (µmol/100 µmol total FA) of these fractions were determined by gas chromatography (GC), and the fatty acid concentrations calculated (27). [U-13C]palmitate and [U-13C]linoleate enrichments were measured in plasma FFA, TG, S_f >400 (chylomicron-TG), S_f 20–400–TG and VLDL-TG FAMEs derivatives using a Δ Plus XP GC-combustion isotope ratio mass spectrometer (Thermo Electron, Bremen, Germany) (30). The tracer-to-tracee ratio (TTR) of a baseline measurement before administration of [U-13C]palmitate was subtracted from the TTR of each sample to account for natural abundance. The TTRs for [U^{13}C]palmitate and [U-13C]linoleate were multiplied by the corresponding unlabeled concentrations to give plasma and lipoprotein tracer concentrations (26).

Lipidomic analysis of VLDL-TG using UHPLC-MS
The UHPLC-QTOFMS analyses were done in a similar manner than described earlier with some modifications (31). UHPLC-QTOFMS system was from Agilent Technologies (Santa Clara, CA, USA) combining 1290 Infinity system and 6545 quadrupole time of flight mass spectrometer (QTOFMS), interfaced with a dual jet stream electrospray (dual ESI) ion source. MassHunter B.06.01 software (Agilent Technologies, Santa Clara, CA, USA) was used for all data acquisition and MZmine 2 was used for data processing (32). ACQUITY UPLC® BEH C18 column (2.1 mm × 100 mm, particle size 1.7 µm) by Waters Corporation (Milford, MA, USA) was used for the UHPLC separation. The lipidomics methods are described in detail in Supplementary Information. The analyses covered most of the main molecular lipids,
including ceramides, dihydroceramides, TGs, DAGs, sphingomyelins, hexosylceramides, phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylserines (PS), and lysophosphatidylcholines. The lipid identification was based on an internal library which had been constructed based on accurate mass measurements in combination with tandem mass measurements. For specific lipids, the composition of fatty acid chains had been determined with separate measurements, and for those the fatty acid composition was specified, e.g. TG(14:0/16:0/18:0).

**Measurement of IHTG content by \(^1\text{H-MRS}\)**

IHTG content was measured by proton magnetic resonance spectroscopy (\(^1\text{H-MRS}\)) performed on a clinical 1.5T Siemens Avanto\textsuperscript{fit} imager. MRS data was analyzed using jMRUI v5.2 software with AMARES algorithm as described (33).

**Lipidomic analysis of the human liver**

We performed re-analysis of TGs and PCs in homozygous carriers (n=7) and non-carriers (n=64) of the PNPLA3 I148M variant in previously described data of human liver lipidome of a separate cohort (5). Briefly, human liver biopsies were obtained during laparoscopic surgery and immediately frozen in liquid nitrogen. Subsequently, molecular lipids were measured using a Q-TOF Premier (Waters, Milford, MA) quadrupole time-of-flight mass spectrometer combined with an Acquity Ultra Performance LC (Waters, Milford, MA) liquid chromatography as previously described (5).
Other analyses from human samples

The fasting plasma glucose was measured using the hexokinase method on an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan). Serum insulin concentration was determined by time-resolved fluoroimmunoassay using an Insulin Kit (AUTOdelfia, Wallac, Turku, Finland). HbA\textsubscript{1c} was measured with immunoturbidometric method (Abbott Laboratories) and plasma ALT, AST, and GGT concentrations using photometric International Federation of Clinical Chemistry methods (Abbott Laboratories). Serum ALT, AST and GGT activities were determined as recommended by the European Committee for Clinical Laboratory Standards and serum TG, total, LDL and HDL cholesterol concentrations using enzymatic kits and an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan). Plasma albumin was measured using a photometric method on an autoanalyzer (Modular Analytics EVO; Hitachi High-Technologies Corporation, Tokyo, Japan).

Cell culture and generation of CRISPR cell lines

Human epidermoid carcinoma A431 cells (ATCC) were cultured in DMEM (Dulbecco's Modified Eagle's Medium) with 10% FBS containing L-Glutamine (2mM) and streptomycin/penicillin (100 U/ml each). Cell culture reagents and solvents were from Gibco/Thermo Fisher, Lonza and Sigma. PNPLA3-ko and I148M -ki cell lines were constructed CRISPR/Cas9-mediated genome editing (34). Briefly, a homology-directed repair template was generated by PCR (primer sequences ATACACCGCTCCAGTCCAAGGAACCTGTCC and ATACGTCGACGCAGTAAGTTTTGCTGCCCG), by using Huh7 genomic DNA as a template, and ligated into pGL3-Basic vector. The construct was transfected into A431 cells together with a vector encoding Cas9, sgRNA targets flanking the mutation
site (sense: CACCGTAGAAGGGGATGAAGC; antisense: AAACGCTTCATCCCCCTTCTAC), and a puromycin selection marker. Clones were isolated after transient selection with puromycin by limiting dilution. Homozygous mutations were validated by genomic PCR. With this protocol, we obtained a homozygous PNPLA3 I148M –ki cell line, as well as a homozygous PNPLA3-ko cell line with a 2-bp deletion after 146C, resulting in a frameshift and premature termination of translation (PNPLA3-ko).

**Lipid analyses from cells**

For the determination of unlabeled lipids, cells were extracted and lipids analysed by high-performance thin layer chromatography as in (35). Click labeling and analyses were performed essentially as described (15, 17). Briefly, for alkyne-FA labeling, cells grown in 12-well plates were incubated at +37°C, 5% CO₂ for 15 min in loading medium containing serum-free DMEM supplemented with 1% fatty acid free BSA, and 100 µM alkyne-linoleate (Cayman Chemical) or alkyne-palmitate (Avanti Polar Lipids). In lipolysis experiments, a cholesterol esterification inhibitor (Sandoz PKF 58-035, 2 µg/ml) was added and the labeling was performed for 1 h. For chase, cells were incubated with serum-free DMEM containing 5% LPDS [lipoprotein-deficient serum, prepared as described in Goldstein et al (1983)], PKF 58-035 (2 µg/ml) and diglyceride acyltransferase (DGAT)-1 and DGAT-2 inhibitors (5 µM each, Sigma PZ0207 and PZ0233) for 15, 30 or 60 min. Lipid extraction, click reaction and analysis of alkyne fatty acid incorporation into selected lipids (TG, 1,2/2,3-DAG, Phosphatidylethanolamine [PE] and PC) by thin layer chromatography was performed as in (17).
**Microscopy**

For lipid droplet analyses, cells were incubated for 24 h with BSA-complexed 100 µM palmitate, oleate, linoleate or a mixture of docosahexaenoic acid [DHA, 22:6(n-3)] and eicosapentaenoic acid [EPA, 20:5(n-3)] (50 µM each) (Sigma Aldrich) for 24 h. The cells were fixed with 4% PFA, stained with lipid droplet stain LD540 (36) (Princeton BioMolecular Research), and imaged with Nikon Eclipse Ti-E N-STORM epifluorescence microscope. Thresholded lipid droplet area as % of total cell area was analysed from micrographs with ImageJ FIJI.

**Statistics**

Continuous variables were tested for normality using the Kolmogorov-Smirnov test. The independent two-sample Student’s t and Mann-Whitney U tests were used to compare normally and non-normally distributed data, respectively. Normally distributed data were reported in means ± standard error of means while non-normally distributed were reported in medians and interquartile ranges. Pearson χ² test was used to evaluate if the distributions of categorical variables differ between the groups. The fatty acid composition of VLDL-TG data was analyzed by a two-way analysis of variance (ANOVA). Areas under the curves (AUC) for ¹³C-18:2/¹³C-16:0 fatty acids in chylomicron-TG and VLDL-TG were calculated using the trapezoid method. The former AUC was analyzed with respect to the latter AUC using linear regression. The UHPLC-MS data were analyzed by relating the ratio of a given VLDL-TG in the PNPLA3¹⁴⁸MM vs. the PNPLA3¹⁴⁸II group to the number of double bonds in that VLDL-TG using linear regression. Statistical analyses were performed by using IBM SPSS Statistics 23.0.0.0 version (IBM, Armonk, NY) and GraphPad Prism 7.0d for Mac OS X (GraphPad Software, La Jolla, CA). A p value of less than 0.05 indicated statistical
significance. For in vitro experiments, statistical significance was determined by a two-tailed Student's t-test using Microsoft Excel.

**Study approval**

The study protocols were approved by the ethics committee of the Hospital District of Helsinki and Uusimaa, Helsinki, Finland. The studies were conducted in accordance with the Declaration of Helsinki. Each participant provided written informed consent after being explained the nature and potential risks of the study.

**Author contributions**

All authors – critical revision of the manuscript for important intellectual content, PKL – study concept and design; acquisition of clinical data; analysis and interpretation of data; drafting of the manuscript; statistical analysis. AN – acquisition of in vitro data; analysis and interpretation of data, MHV – study design and supervision; acquisition of in vitro data; analysis and interpretation of data; drafting of the manuscript. CT – acquisition of in vitro data, EI, SLB – acquisition of clinical data, YZ – statistical analysis, AH, NL – acquisition and analysis of magnetic resonance data, MP – recruiting from the National FINRISK cohort, MO-M – genotyping, MO, TH – acquisition of lipidomics data, LH – acquisition of gas chromatography and mass spectrometry data; study concept and design; analysis and interpretation of data, EI – study concept and design; analysis and interpretation of data; drafting of the manuscript; study supervision, HY – study concept and design; analysis and interpretation of data; drafting of the manuscript; study supervision.
Acknowledgements

We thank Anne Salo, Aila Karioja-Kallio, Päivi Ihamuotila, and Pentti Pölönен for their excellent technical assistance, Siiri Luukkonen for graphical assistance, Shiqian Li for his generous help in designing A431 CRISPR cell lines, and the volunteers for their help. This study was supported by research grants from the Academy of Finland (HY grant no. 309263; EI grants no. 282192, 307415, 312491), EU H2020 project ‘Elucidating Pathways of Steatohepatitis’ (HY EPoS grant no. 634413), and the H2020-JTI-IMI2 EU project 777377-2 Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) (HY), EVO (HY), Paulo (PL), Sigrid Juselius (HY, PL, EI), Finnish Medical (PL), Alfred Kordelin (PL) and Liv och Hälsa (MH-V) foundations.
REFERENCES


FIGURES AND FIGURE LEGENDS

Figure 1. Concentrations of (A) plasma TGs, (B) free fatty acids, (C) VLDL-TG, (D) chylomicron-TG, (E) glucose and (F) serum insulin in the PNPLA3^{148MM} and PNPLA3^{148II} groups in the fasting state (0 min) and during the postprandial period. Data are shown as mean±SEM. The blue lines and circles denote the PNPLA3^{148II} (n=14) group and the red lines and squares the PNPLA3^{148MM} (n=12) group. There were no significant differences between the groups as determined using 2-way ANOVA.
Figure 2. Differences between distinct VLDL-TGs in the PNPLA3\textsuperscript{148MM} vs. PNPLA3\textsuperscript{148II} groups according to the number of double bonds. Panels show linear regression lines between the number of double bonds in VLDL-TGs and the log\textsubscript{2} fold-change of absolute concentrations of corresponding VLDL-TGs in the PNPLA3\textsuperscript{148MM} (n=12) vs. the PNPLA3\textsuperscript{148II} (n=14) group (A) in the fasting state (0 min), (B) 120 min, (C) 300 min and (D) 420 min following the meal. Each circle denotes a distinct VLDL-TG species. Significance was determined using linear regression analysis.
Figure 3. Differences in the composition and handling of VLDL-TG fatty acids in the PNPLA3<sup>148MM</sup> vs. the PNPLA3<sup>148II</sup> groups. (A) Percentage of distinct fatty acids of total unlabelled fatty acids in VLDL-TG in the PNPLA3<sup>148MM</sup> (red bars, n=12) and PNPLA3<sup>148II</sup> (blue bars, n=14) groups in the fasting state. (B) Fold change in the percentage of distinct fatty acids of total unlabeled fatty acids in VLDL-TGs in the PNPLA3<sup>148MM</sup> (n=12) vs. the PNPLA3<sup>148II</sup> (n=14) group in the fasting state (0 min) and during the postprandial period. X-axis denotes distinct fatty acids and y-axis denotes postprandial time. Each square represents log<sub>2</sub> fold-change of the percentage of a distinct fatty acid of total fatty acids in VLDL-TG in the PNPLA3<sup>148MM</sup> (n=12) vs. the PNPLA3<sup>148II</sup> (n=14) group in that time point. (C-D) Percentage of unlabeled
polyunsaturated fatty acid linoleate (18:2) (C) and saturated fatty acid palmitate (16:0) (D) of total fatty acids in VLDL-TG in the PNPLA3$^{148\text{MM}}$ (red squares and lines, n=12) and PNPLA3$^{148\text{II}}$ (blue circles and lines, n=14) groups in the fasting state and during the 420 min postprandial period. (E) Linear regression lines between the number of double bonds in VLDL-TG fatty acids and the log$_2$ fold-change of absolute concentrations of corresponding VLDL-TG fatty acid in the PNPLA3$^{148\text{MM}}$ (n=12) vs. the PNPLA3$^{148\text{II}}$ (n=14) group in the fasting state (0 min; black circles), 120 min (red squares), 180 min (green triangles pointing up), 240 min (blue triangles pointing down), 300 min (purple diamonds), 360 min (orange circles) and 420 min (turquoise squares). (F) Ratio of $^{13}$C-18:2 to $^{13}$C-16:0 fatty acids in plasma VLDL-TG related to the corresponding ratio in the chylomicron precursor pool in the PNPLA3$^{148\text{MM}}$ (red squares and lines, n=12) and the PNPLA3$^{148\text{II}}$ (blue circles and lines, n=14) groups. Data are shown as mean±SEM. * p < 0.05. Significance was determined using 2-tailed Student’s t test for unpaired data, 2-way ANOVA and linear regression as appropriate.
Figure 4. Characterization of lipid storage in homozygous PNPLA3-148I, PNPLA3-148M and PNPLA3-ko A431 cells. Cells were incubated for 24 h in the presence of 100 µM palmitate, oleate, linoleate or mixture of DHA and EPA (50 µM each), fixed and stained with lipid droplet dye LD540. Scale bar: 10 µm. Bars: % of cell area occupied by lipid droplets ± SEM. N of cells 62-76. * p < 0.05 (two-tailed Student’s t-test).
Figure 5. Partitioning of alkyne-labeled fatty acid in homozygous PNPLA3-148I, PNPLA3-148M and PNPLA3-ko A431 cells. (A) Cells were incubated for 15 min with 100 µM alkyne-palmitate, then extracted, click-reacted and analyzed by TLC. Bars: % of incorporated alkyne-palmitate in indicated lipid species ± SEM. N=9 from
3 individual experiments. (B) Cells were incubated for 15 min with 100 µM alkyne-linoleate and analyzed as in (A). Bars: % of incorporated alkyne-linoleate in indicated lipid species ± SEM. N=9-17 from 4-6 individual experiments,* p < 0.05 (two-tailed Student’s t-test) (C) Cells were incubated for 1h min with 100 µM alkyne-linoleate in the presence of cholesterol esterification inhibitor. After labeling, cells were either collected (0 min chase) or further incubated in lipoprotein-deficient medium supplemented with cholesterol esterification and DGAT inhibitors for 15, 30 or 60 min, then analysed as in (A). Bars: % of incorporated alkyne-linoleate in indicated lipid species, normalized to PNPLA3-148I cells at 0 min chase ± SEM. N=5-8 from 3-4 individual experiments,* p < 0.05 (two-tailed Student’s t-test).
Figure 6. Polyunsaturated TGs are enriched while PCs are deficient in the human liver in homozygous carriers (PNPLA3^{148MM}) as compared to non-carriers (PNPLA3^{148II}) of the PNPLA3 I148M variant. X-axis denotes log₂ fold-change in hepatic concentration of a given lipid in PNPLA3^{148MM} (n=7) as compared to PNPLA3^{148II} (n=64) group. Y-axis denotes negative logarithm of p-value of t-test comparing hepatic concentrations of a given lipid in PNPLA3^{148MM} as compared to PNPLA3^{148II} group. Red squares denote TGs and blue circles PCs. Horizontal dashed line represents -\log_{10}(0.05). Each symbol represents distinct hepatic lipid species. Lipid species that were significantly decreased in the PNPLA3^{148MM} as compared to the PNPLA3^{148II} group are listed on the left side of the figure, while those that were increased are listed on the right side in the order of significance. Data in this figure are from separate liver biopsy cohort described earlier (5).
Table 1. Clinical characteristics of the subjects.

<table>
<thead>
<tr>
<th></th>
<th>PNPLA3&lt;sup&gt;148II&lt;/sup&gt;</th>
<th>PNPLA3&lt;sup&gt;148MM&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group size (n)</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>Age (years)</td>
<td>52.4 ± 1.8</td>
<td>53.1 ± 2.2</td>
</tr>
<tr>
<td>Gender (% women/men)</td>
<td>79/21</td>
<td>83/17</td>
</tr>
<tr>
<td>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>31.8 ± 1.5</td>
<td>31.8 ± 2.0</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>99.0 (92.8 – 109.5)</td>
<td>98.0 (89.1 – 114.3)</td>
</tr>
<tr>
<td>fP-Glucose (mmol/l)</td>
<td>5.7 (5.3 – 6.0)</td>
<td>6.0 (5.5 – 6.2)</td>
</tr>
<tr>
<td>fS-Insulin (mU/l)</td>
<td>6.2 (3.4 – 9.1)</td>
<td>6.0 (4.4 – 11.7)</td>
</tr>
<tr>
<td>fP-Triglycerides (mmol/l)</td>
<td>0.9 (0.8 – 1.1)</td>
<td>0.9 (0.6 – 1.4)</td>
</tr>
<tr>
<td>fP-HDL cholesterol (mmol/l)</td>
<td>1.49 ± 0.08</td>
<td>1.58 ± 0.16</td>
</tr>
<tr>
<td>fP-LDL cholesterol (mmol/l)</td>
<td>3.3 ± 0.2</td>
<td>3.4 ± 0.2</td>
</tr>
<tr>
<td>P-AST (IU/l)</td>
<td>25 (20 – 31)</td>
<td>27 (24 – 30)</td>
</tr>
<tr>
<td>P-ALT (IU/l)</td>
<td>21 (16 – 35)</td>
<td>24 (19 – 33)</td>
</tr>
<tr>
<td>P-GGT (U/l)</td>
<td>17 (13 – 48)</td>
<td>24 (21 – 35)</td>
</tr>
<tr>
<td>P-Albumin (g/l)</td>
<td>36.6 ± 0.6</td>
<td>35.7 ± 0.7</td>
</tr>
<tr>
<td>IHTG (&lt;sup&gt;1&lt;/sup&gt;H-MRS, %)</td>
<td>1.8 (1.0 – 6.7)</td>
<td>6.3 (4.5 – 14.6)*</td>
</tr>
</tbody>
</table>

Data are in n, %, means ± SEM or median (25th-75th percentile), and statistical tests are Student t-test, Mann-Whitney U-test and Pearson $\chi^2$-test, as appropriate. *p ≤ 0.05 compared to the PNPLA3<sup>148II</sup> group. IHTG, intrahepatic triglycerides.